Clinical trials: B-Cell Non-Hodgkin Lymphoma-Refractory
Diffuse Large B Cell Lymphoma
CyBeR Association in Relapsed/Refractory DLBCL
Forty percent of patients with diffuse large B cell lymphoma (DLBCL) have primary refractory or relapsed disease (R/R). For these fit patients, standard treatment in second line therapy is high dose therapy with autologous stem…
- Trial name
- CyBeR-Lymph (NCT02758925)
- Testing
- Rituximab, Bendamustine, Cytarabine
- Volunteers
- 78 people
- Sponsor
- University Hospital, Caen
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
This open-label, multi-cohorts, phase 1/2 study has the primary objective of comparing decitabine-primed tandem CART 19/20 solo, with decitabine-primed tandem CART 19/20 plus chidamide, decitabine-primed tandem CART 19/20 plus…
- Trial name
- NCT04553393
- Testing
- Chidamide, Decitabine, Chidamide and Decitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06300528
- Testing
- Pemigatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Anemia, Chronic Myeloproliferative Disorders
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00301912
- Testing
- filgrastim, busulfan, fludarabine phosphate
- Where
- United States
- Sponsor
- University of California, San Francisco
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for…
- Trial name
- CAR-T for NHL (NCT06698484)
- Testing
- CAR-T cells
- Where
- Malaysia
- Volunteers
- 20 people
- Sponsor
- National University of Malaysia
NHL, Large Cell Lymphoma
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Background: One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person.
- Conditions
- NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL
- Trial name
- NCT02315612
- Testing
- CD22-CAR
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
RATIONALE: Acupuncture may be effective in relieving mucositis-related pain caused by chemotherapy in patients undergoing stem cell transplantation.
- Trial name
- NCT00060021
- Testing
- acupuncture therapy, management of therapy complications, pain therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase II, single institution, single-arm, open-label study of oral dasatinib monotherapy administered to subjects with relapsed or refractory aggressive DLBCL.
- Trial name
- NCT00918463
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255684
- Testing
- graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas
Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019.
- Conditions
- CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas
- Trial name
- NCT02650999
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-Hodgkin's Lymphoma
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
- Trial name
- NCT00042666
- Testing
- LY317615
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease.
- Trial name
- NCT00768339
- Testing
- AEG35156 antisense IV infusion
- Where
- 7 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Aegera Therapeutics
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00060372
- Testing
- ipilimumab, therapeutic allogeneic lymphocytes
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
The probability to achieve CR with R-chemotherapy in patients failing a rituximab containing first line regimen is quite low, in particular in cases with non GCB profile.
- Trial name
- FIL_VERAL12 (NCT01805557)
- Testing
- R-DHAP, BR-DHAP
- Where
- 24 sites in Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma, B-Cell, Marginal Zone
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.
- Trial name
- NCT03093831
- Testing
- Ibrutinib
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- National Cancer Centre, Singapore
Leukemia, Lymphoma
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00003913
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- 23 sites in United States
- Volunteers
- 390 people
- Sponsor
- Fred Hutchinson Cancer Center
B-Cell Non-Hodgkin Lymphoma
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- CT1190B (NCT07032324)
- Testing
- CAR T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Qian Wenbin
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Trial name
- SEARCH (NCT03992339)
- Testing
- ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
- Where
- 18 sites in China
- Volunteers
- 60 people
- Sponsor
- Antengene Corporation
Acute Lymphoblastic Leukemia
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
This study is a multicenter, prospective, interventional clinical trial aimed at recruiting relapsed/refractory Ph-ALL patients at multiple stem cell transplantation centers, including the Stem Cell Transplantation Center of the…
- Trial name
- NCT06087419
- Testing
- chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
This phase I trial studies the side effects and best dose of alisertib and romidepsin in treating patients with B-cell or T-cell lymphomas that have returned after a period of improvement (relapsed) or have not responded to…
- Conditions
- MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01897012
- Testing
- Alisertib, Laboratory Biomarker Analysis, Romidepsin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.